Dr. Cushman is The Distinguished Professor of Medicinal Chemistry at Purdue University and the inventor of the Indenoisoquinoline compounds that form the intellectual property of Gibson Oncology. He is an expert in and leads a team dedicated to design and synthesis of a variety of molecules that interact with specific enzymes and membrane-bound receptors.
He trained for both his Pharm.D. and Ph. D. Degrees at the University of California. Medical Center, San Francisco before completing a post-doc at the Massachusetts Institute of Technology. Dr. Cushman has been at Purdue virtually his entire career and has been given many honors including a Senior Fulbright Scholarship, membership as a Fellow of the American Association for the Advancement of Science, Associate Editor of the Journal of Medicinal Chemistry, and the Chaney Scholar Award for Exceptional Research by Purdue University.
Dr. Cushman has published over 330 peer reviewed articles. In addition, he has over 35 patents published.
Gibson Oncology,LLC is composed of proven academic researchers and bio tech entrepreneurs who are excited to be developing effective and safer novel oncology drugs to treat resistant cancers with a focus on children.